EU faces world's fastest growing HIV epidemic

Marshall, Sarah Jane
April 2004
Bulletin of the World Health Organization;Apr2004, Vol. 82 Issue 4, p310
Academic Journal
Focuses on the increasing growth rates of HIV infection in European Union countries. Impact of HIV/AIDS epidemic with economic and social development; Percentage of HIV-infected people receiving antiretroviral treatment; People with high risk of contracting HIV.


Related Articles

  • THE EUROSIDA STUDY: REGIONAL DIFFERENCES IN THE HIV-1 EPIDEMIC AND TREATMENT RESPONSE TO ANTIRETROVIRAL THERAPY AMONG HIV-INFECTED PATIENTS ACROSS EUROPE -- A REVIEW OF PUBLISHED RESULTS. Podlekareva, Daria; Bannister, Wendy; Mocroft, Amanda; Abrosimova, Ludmila; Karpov, Igor; Lundgren, Jens D.; Kirk, Ole // Central European Journal of Public Health;2008, Vol. 16 Issue 3, p99 

    EuroSIDA is a pan-European observational study that follows 14,265 HIV-infected patients from 31 European countries, Israel and Argentina, of which 2,560 are patients from eastern Europe (EE). The study group has performed several analyses addressing regional differences in the HIV-epidemic...

  • Cure call to mark AIDS anniversary. KATABIRA, ELLY // Nursing Review (1175-2904);Jul2011, Vol. 12 Issue 3, p18 

    The author discusses the need to find a cure for people living with HIV. According to the author, there are compelling evidence that HIV treatment is also HIV prevention and that expanding antiretroviral therapy has preventative benefits for the entire community. As such, the International AIDS...

  • Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study. Panos, George; Samonis, George; Alexiou, Vangelis G.; Kavarnou, Garyfallia A.; Charatsis, Gerasimos; Falagas, Matthew E. // Current HIV Research;May2008, Vol. 6 Issue 3, p257 

    HAART has substantially decreased mortality and morbidity among HIV-infected patients. We retrospectively analyzed morbidity and mortality in a cohort of HIV-infected adult patients with prolonged and frequent follow up (1987-2006). The study was divided in pre-HAART and HAART period for...

  • Modelling T4 cell count as a marker of HIV progression in the absence of any defense mechanism. Yadavalli, Venkata S. Sarma; Labeodan, Moremi Morire OreOluwapo; Udayabaskaran, Swaminathan; Forche, N. // Orion;2010, Vol. 26 Issue 2, p113 

    The T4 cell count, which is considered one of the markers of disease progression in an HIV infected individual, is modelled in this paper. The World Health Organisation has recently advocated that countries encourage HIV infected individuals to commence antiretroviral treatments once their T4...

  • Partner protection. Coghlan, Andy // New Scientist;4/28/2012, Vol. 214 Issue 2862, p4 

    The article discusses a recommendation from the World Health Organization (WHO) to immediately give any person with HIV, whose partner is not infected, antiretroviral drugs to prevent HIV transmission.

  • PAF63 High prevalence of distal sensory polyneuropathy in treated and untreated Tanzanians with HIV. A cross-sectional survey. S Mullin // Journal of Neurology, Neurosurgery & Psychiatry;Nov2010, Vol. 81 Issue 11, pe17 

    BACKGROUND: Distal sensory polyneuropathy (DSP) is a well-known complication both of advanced HIV disease and of antiretroviral treatments (ARTs), in particular stavudine and didanosone. Both are widely used in sub-Saharan Africa. There are few data documenting the prevalence of HIV DSP in...

  • The effect of HIV and antiretroviral therapy on characteristics of pulmonary tuberculosis in northern Malawi: a cross-sectional study. Munthali, Lumbani; Khan, Palwasha Y.; Mwaungulu, Nimrod J.; Chilongo, Femia; Floyd, Sian; Kayange, Michael; Glynn, Judith R.; French, Neil; Crampin, Amelia C. // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background HIV infection reduces the likelihood that individuals with pulmonary tuberculosis are smear positive and that they have cavitatory disease. Antiretroviral therapy (ART) may shift the pattern of disease to be more similar to that of HIV negative patients. This would aid diagnosis-...

  • The START Trial: Definitive Evidence to Treat All HIV-Positive Persons Regardless of CD4 Counts. Tabernilla, Andrés; Poveda, Eva // AIDS Reviews;Jul-Sep2015, Vol. 17 Issue 3, p187 

    The article discusses the Strategic Timing of Anti-Retroviral Treatment study which revealed evidence of the effectiveness of earlier antiretroviral treatment for all HIV-infected people.

  • Three-Class Antiretroviral Resistance in a Patient with Acute HIV-1 Infection. Gentz, Mark; Levin, Todd P.; Klibanov, Olga M.; Feingold, Anat; Condoluci, David V. // AIDS Patient Care & STDs;Nov2006, Vol. 20 Issue 11, p741 

    Antiretroviral resistance in treatment-naïve patients with HIV-1 infection is on the rise in both resource-rich and resource-poor countries. We report a case of three-class primary antiretroviral resistance detected by a genotypic assay in a 19-year-old woman with acute HIV-1 infection. Her...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics